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Summary Bacteriochlorin a (BCA) is a second-generation photosensitizer that is effective in tumour destruction upon illumination with light of
a wavelength of 760 nm. Tissue penetration by light at this wavelength is greater compared with wavelengths at which commonly used
photosensitizers are illuminated, making it possible to treat larger tumours. In a model of experimental liver metastases in rats, we measured
lesion sizes after interstitial illumination of tumours at different times after intravenous administration of BCA (10 mg kg-' bodyweight), as well
as BCA concentrations in liver and tumour tissue. In both, BCA concentrations showed a rapid decline within the first 4 h, followed by a slow
decrease over the next 20 h, suggesting biphasic pharmacokinetics. No selective uptake in tumour tissue was observed. A near-linear
relationship was found between lesion sizes and liver and tumour BCA concentrations, suggesting that optimal results with photodynamic
therapy (PDT) could be obtained by illumination within a short time interval after administration, when tissue concentrations are highest. No
severe liver toxicity was observed as indicated by serum ALAT levels. However, in all tumours evaluated, islands of vital-looking cells were
present leading to tumour regrowth within 35 days. In view of the obtained lesion diameters of approximately 13 mm after BCA-PDT and the
rapid clearance rate of BCA, the concept of a near-infrared absorbing photosensitizer for PDT of liver tumours is a potential interesting strategy.
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Photodynamic therapy (PDT) is becoming an accepted treatment
for cancer, in which tumour destruction is based on accumulation
of a photosensitizing drug in tumour tissue and subsequent illumi-
nation with light of a specific wavelength (Gomer, 1991). The
light matches an absorption peak of the drug, which becomes
activated at illumination. The activated photosensitizer reacts with
available oxygen and causes production of reactive oxygen
species, such as singlet oxygen. Singlet oxygen can cause direct
damage to many cellular sites, such as plasma membranes, micro-
somes, mitochondria and nuclei (Henderson and Bellnier, 1989).
PDT also induces vasoconstriction and blood flow stasis so that
tumour cells die ofanoxia (Fingar et al, 1990). The combination of
a photosensitizer, light and oxygen is required to induce the photo-
chemical reaction.
To date, the most commonly used photosensitizers in clinical
studies are haematoporphyrin derivative (HpD), a mixture of
various porphyrins and a purified form, Photofrin II. Photofrin is
excited with light at a wavelength around 630 nm. Although
Photofrin has proven to be an effective photosensitizer, there are
some limitations: at a wavelength of630 nm, tissue penetration of
light is limited and light absorption of the photosensitizer is low
(Wilson and Patterson, 1986), and Photofrin induces photosensiti-
zation of the skin, which makes it necessary for patients to avoid
exposure to bright light for 4-8 weeks after treatment (Bellnier
and Dougherty, 1989). These limitations can be overcome by
'second-generation' photosensitizers, which usually have a major
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absorption peak above 650 nm and induce less photosensitization
ofthe skin.
Bacteriochlorin a (BCA) is a second-generation photosensitizer
and is a very potent photosensitizer. In vitro it photo-oxidizes a
number of amino acids and effectively kills mouse fibroblasts and
human bladder carcinoma cells (Beems et al, 1987). In vivo, it
induces tumour necrosis in hamster Greene melanoma in the ante-
rior eye chamber of white rabbit, in mammary tumours in rat and
in RIF tumours in mice (Schuitmaker et al, 1990; van Leengoed
et al, 1993; van Geel et al, 1995). BCA has an absorption peak at
760 nm, a wavelength at which tissue penetration is optimal. It is
rapidly cleared from tissues and induces only minor skin photo-
sensitivity (van Leengoed et al, 1993).
In the past years, mainly malignancies ofthe urinary tract, skin,
upper respiratory tract and gastrointestinal tract (Fisher et al, 1995)
have been treated with PDT, but it has rarely been applied to deep-
seated tumours, such as liver tumours. The use of PDT for liver
tumours has been restricted as liver tissue accumulates photosensi-
tizers more efficiently than malignant tissue (Bugelski et al, 1981).
Superficial illumination will thus result in substantial liver
necrosis and, because oflimited light penetration, it will be impos-
sible to treat deep-seated or larger solid tumours. This can be over-
come by delivering light directly into the tumour - a treatment
called interstitial therapy (Marijnissen et al, 1992). The ability of
interstitial photodynamic therapy (IPDT) to cause destruction of
tumours within the liver has been demonstrated in animal studies,
using HpD and Photofrin (Holt et al, 1985; van Hillegersberg et al,
1992). Although tumour destruction was accomplished, there was
also considerable damage to surrounding liver tissue, and the
amount of tissue that could be treated was limited. New, second-
generation photosensitizers could possibly establish a more selec-
tive accumulation in tumour tissue, and illumination with light
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Table 1 Concentrations of BCA and liver to tumour ratios at different time intervals after intravenous injection
Time (h) [Liver tissue] gg mg-' [Tumour tissue] 9g mg-1 Liver/tumour ratio
1 31.90±6.2 17.55+2.19 2.0+0.3
2 18.97 ± 0.78 9.6 + 0.23 2.0 + 0.2
4 13.78 ± 0.39 9.0+ 0.56 1.2 ± 0.1a
24 5.55 ± 0.27 5.78 ± 0.27 0.9+±O.a
[Liver tissue], mean ± s.e.m. concentration of BCA in liver tissue; [tumour tissue], mean + s.e.m. concentration of BCA in tumour tissue. The concentration is
expressed as jig mg-1 wet tissue. Liver/tumour ratio is expressed as mean + s.e.m. BCA concentration ratio between liver and tumour tissue for each time point,
after determination of the L/T ratio for each animal. aSignificantly (P < 0.05) lower than 1 and 2 h after injection.
Table 2 Lesion size and percentage of tumour necrosis 2 days after IPDT
with BCA
Time (h) Lesion size (mm2) Tumour necrosis (%)
1 141.8 ± 21.9 95.5+ 4.3
4 95.3+ 20.7 97.8 ± 1.3
24 66.2 ± 26.8 72.1 ± 8.5
Control 63.0 ± 2.5
Lesion size, mean ± s.e.m. of the total amount of damage (liver and
tumour) measured at the surface of the liver as calculated with the formula
1/4 X R, R2. The percentage of tumour necrosis is expressed as mean ±
s.e.m. of the percentage of tumour necrosis 2 days after treatment, assessed
on microscopic sections of tumours. Animals in the control group were
treated either with light or with BCA only.
further penetrating into tissue could result in larger volumes of
necrosis. We choose BCA as photosensitizer because ofthe poten-
tial deep penetration oflight of760 nm into tissue. The aim ofthis
study was to investigate the macroscopic and microscopic effect of
interstitial illumination on liver and tumour tissue and to correlate
induced changes with BCA tissue concentrations at different time
intervals after illumination.
MATERIALS AND METHODS
Tumour model
Male Wag/Rij rats (Harlan CPB, Zeist, The Netherlands) weighing
245-315 g were used in all experiments. The animals had access
to food and water ad libitum. A total of 60 animals was used. In
these experiments, we used the CC531 colon adenocarcinoma cell
line, which is moderately differentiated, syngeneic and trans-
plantable to Wag/Rij rats. Tumour cells were cultured on RPMI
1640 (Dutch modification) supplemented with 2 mM L-glutamine
(Gibco, Grand Island, NY, USA), 10% heat-inactivated fetal calf
serum, 100 U ml-l penicillin and 0.1 mg ml-' streptomycin
sulphate. At laparotomy, under ether anaesthesia, 5 x 105 tumour
cells were injected subcapsulary into the liver. To determine tissue
concentrations, three tumours per rat were induced (left lateral
lobe, upper right lobe and lower right lobe), and for the IPDT
study one tumour per rat was induced (left lateral lobe). Two
weeks after injection, when tumours had reached a diameter of 5-
7 mm, they were treated. The experiments were approved by the
Animal Welfare Committee of the Leiden University Medical
Centre, and animals received care in accordance with established
guidelines.
Photosensitizer
BCA was obtained as described by Schuitmaker et al (1990).
Briefly, bacteriochlorophyll a, extracted from the photosynthetic
bacterium Rhodospirillum rubrum, was purified according to the
method ofOmata and Murata (1983). Saponifying bacteriochloro-
phyll a, as described by Oster et al (1964), yielded bacteriochloro-
phyllin a, which was subsequently subjected to acid hydrolysis.
The BCA formed was extracted with ethylacetate. Ethylacetate
was evaporated and BCA was lyophilized overnight and stored at
-20°C in the dark under nitrogen. Purity of the pigments was
checked with thin-layer chromatography and spectrophotometric
methods.
BCA was dissolved in a 10% chremophor suspension in 0.9%
sterile saline and was injected intravenously in a femoral vein. All
animals received a dose of 10 mg kg-' and were kept in subdued
light to avoid possible side-effects.
Determination of photosensitizer concentration
To determine BCA tissue concentrations and to assess concentra-
tion ratios between liver and tumour tissue, we used 24 rats,
having three tumours in the liver (14 days after inoculation). At 1,
2, 4 and 24 h after BCA administration, the animals were killed
and the liver was removed, tumours were dissected and immedi-
ately frozen in liquid nitrogen. Liver tissue, from at least 0.5 cm
away from the tumour, was also frozen in liquid nitrogen. The
samples were stored at -20°C until analysis. Concentrations of
BCA in tissue samples were determined using fluorescence
measurements. Tissue samples were weighed and homogenized,
on ice and under subdued light, in 3 ml of methanol (Baker
Chemicals, The Netherlands). The homogenate was centrifuged
(2000 r.p.m. for 5 min), and fluorescence in the supernatant was
measured with a spectrofluorometer (Aminco SPF 500) at 685 nm
(± 10 nm) using an excitation wavelength of 410 nm (± 5 nm).
Fluorescence of known BCA concentrations in methanol was
measured and plotted in a concentration scale, which was used to
determine tissue concentrations. After correction for the weight of
the samples, the concentration of BCA was expressed as ,ug mg-'.
From each rat, two tumour and two liver measurements were
obtained and the concentration ratio between liver and tumour
tissue was calculated. The mean concentration and mean concen-
tration ratio ± standard error of the mean (s.e.m.) were calculated
for each time point (n = 5).
Interstitial photodynamic therapy
To assess the effect of interstitial illumination, 36 rats bearing one
liver tumour were used. They were randomly assigned to four
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Figure 1 Relationship between BCA concentrations and PDT-induced
lesions. Lesion size represents the mean lesion sizes (mm2), measured 48 h
after PDT treatment, consisting of both liver and tumour damage. BCA
concentration represents the mean ± s.e.m. BCA concentration (gg mg-') in
both liver and tumour tissue. Each point represents the mean of five animals.
+, Tumour; A, liver
groups: three experimental groups [BCA + illumination at 1
(n = 6), 4 (n = 12) and 24 (n = 6) h after i.v. injection] and one
control group [illumination only (n = 6), BCA injection only
(n = 2) and no treatment (n = 4)]. At laparotomy under ether
anaesthesia, the liver was exposed and a 17-gauge Venflon
(BOC Ohmeda, Sweden) was inserted in the tumour, through
which a 600-ltrm optical fibre with a plain cut fibre tip was
positioned. Tumours were illuminated with 760nm delivered
from a custom-made diode laser (Philips Optoelectronic
Centre, Eindhoven, The Netherlands), set at a power density of
100mW cm-2. The total amount of energy delivered to each
tumour was 100 J (100 mW for 1000 s).
All animals were killed 48 h after treatment, except for six
animals treated 4 h after BCA administration and two animals
from the control group: these animals were allowed to survive for
35 days to determine the extent of tumour regrowth after treat-
ment. In these remaining rats (n = 6 + 2), a laparotomy was
performed 7 days after illumination to measure tumour size and to
determine the short-term effect on tumour growth. In all animals,
the size of PDT-induced lesions was measured using sliding
callipers and calculated with the formula: 1/4 t RI R2, where R,
and R, are diameters perpendicular to each other. After fixation in
formalin, livers were cut through the largest diameter ofthe lesion,
embedded in paraffin wax, sectioned (2,m) and stained with
haematoxylin and eosin (HE). The percentage of tumour necrosis
was assessed at light microscopy by counting 'viable' and
B
Figure 2 A histological section 2 days after PDT treatment of (A) necrotic
liver tissue with a zone of viable hepatocytes around the portal vessels (P),
whereas the hepatocytes around the central vein (C) did not survive the
treatment. (B) Evident is the adherence of granulocytes to the vessel wall of
a larger vessel in an area of necrotic liver tissue. Magnification 100 x
'necrotic cells' in the tumour: using a standard microscopic grid,
on one HE-stained section (magnification 100x), all cells at a
crossing of lines were evaluated and assessed as being 'viable' or
'necrotic' according to pathologists' guidelines.
Blood samples (0.5 ml) were taken by orbital puncture immedi-
ately before and 2 days after treatment to determine levels of
serum alkaline phosphatase (AP), aspartate aminotransferase
(ASAT) and alanine aminotransferase (ALAT).
Table 3 Changes in serum levels of alkaline phosphatase, ASAT and ALAT, measured directly before treatment and 2 days after treatment
Group AP ASAT ALAT
Before e after P-value Before - after P-value Before -* after P-value
1 74-37 0.019a 63-164 0.011a 18-82 QO.OQa
2 121 -*91 Q.O1a 126-127 0.935 31 -*79 Q.QQQa
3 122-93 O.01a 128-67 O.01a 32 37 0.251
Controls 115 - 93 0.014a 86 - 91 0.763 31 - 36 0.53
Changes in serum enzyme levels after illumination at different time intervals after BCA administration: group 1 (n = 6), 1 h after BCA administration; 2 (n = 6),
4 h after BCA administration; 3 (n = 6), 24 h after BCA administration. AP, alkaline phosphatase; ASAT, aspartate aminotransferase; ALAT, alanine
aminotransferase. aSignificant difference (P< 0.05).
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Statistical analysis
Tissue concentrations were determined from two measurements
and the mean concentration was calculated for each treatment
group. Liver (L) to tumour (T) concentration ratios were calcu-
lated for each animal and the mean L/T ratio was determined for
each treatment group. Values were expressed as mean ± s.e.m. for
each time point (n = 6). An analysis of variance (ANOVA) using
the least significant difference (LSD) test was used to analyse the
relation between time after injection and liver to tumour ratio. A
P-value of < 0.05 was considered as significant.
RESULTS
Tissue concentrations
Concentrations of BCA in liver and tumour tissue are shown in
Table 1: 1 h after BCA administration, both liver and tumour
tissues contained high concentrations ofBCA. The relatively rapid
decrease in the first hours after administration was followed by a
slow decline, suggesting biphasic pharmacokinetics. Whereas
during the first 2 h liver BCA concentrations were twice that of
concentrations in tumour tissue, this difference gradually disap-
peared. L/T ratios at 1 and 2 h were significantly higher (P < 0.05)
than those at 4 and 24 h after injection, at which time most of the
photosensitizer was cleared from liver and tumour tissue.
Interstitial photodynamic therapy effect
The mean tumour size before treatment was 30.9 ± 2.8 mm2 (n =
36), and there was no significant difference in tumour size between
the different treatment groups. Interstitial illumination was well
tolerated, andduring illumination the liver surface whitened, unless
illumination occurred 24 h after BCA administration; this pale
aspect changed into dark red immediately after illumination. Two
days after treatment, at resection, induced lesions were circular
shaped and had a homogeneous white aspect, except for lesions in
animals treated 24 h after BCA administration, which were
inhomogeneous and irregular. Interstitial illumination of BCA-
containing tissue resulted in extensive necrosis visible on the liver
surface. Tumours lay within a necrotic area, so lesion sizes repre-
sent tumour necrosis as well as necrosis of surrounding liver tissue.
Mean lesion sizes are shown in Table 2. Illumination 1 h after BCA
administration induced the largest lesions. The mean lesion diam-
eter was 13.5 ± 1.7 mm, with a maximum diameter of 16.2mm in
this group. In the group treated 4 h after BCA administration, lesion
sizes were significantly lower than at 1 h. The mean diameter in
this group was 11.0 ± 1.3 mm. Lesion sizes in animals treated 24 h
afterinjection were significantly less than at 4 h.
Correlating lesion sizes with tissue concentrations showed a
near-linear relation for both liver and tumour tissue (Figure 1).
On microscopic examination, a sharp boundary between
necrotic and viable liver tissue was observed, except when illumi-
nation was performed 24 h after BCA administration, when
necrotic areas were inhomogeneously spread throughout the
lesion. Vital-looking hepatocytes were observed around portal
veins at the rim of lesions, whereas no such cells were found
around central veins (Figure 2). This phenomenon also occurred in
animals treated I and 4 h after BCA administration, although to a
lesser extent; the zone of viable hepatocytes around vessels clearly
increased with the time interval after BCA injection. Larger
vessels in the liver survived treatment when they were located at
the periphery of the lesion, and in all cases, throughout the entire
lesions, massive inflammatory responses were seen, as illustrated
by adherence of granulocytes to vessel walls (Figure 2).
At the higher BCA concentration levels, more than 95% of
tumour tissue had a necrotic aspect assessed 2 days after intersti-
tial illumination, but islands of vital-looking tumour cells could
always be identified microscopically. In all treated animals that
were allowed to survive beyond 48 h, tumour regrowth occurred.
At laparotomy, 7 days after treatment, the mean tumour size in
treated animals (n = 6) was 90.1 mm2, and in untreated animals
(n = 2) it was 154.3 mm2. However, 35 days after treatment
mean tumour sizes were 204.6 and 204.8 mm2 respectively.
Changes of serum AP, ASAT and ALAT levels are shown in
Table 3. Illumination I h after BCA administration resulted in a
significant increase in both ASAT and ALAT levels, with
AASAT/AALAT ratio > 1. Upon illumination 4 hours after admin-
istration, there was a significant increase in the ALAT level only
(AASAT/AALAT ratio < 1). After illumination 24 h after BCA
administration, no increase in ASAT and ALAT levels occurred.
DISCUSSION
PDT has proven to be effective in experimental tumour destruction
and growth reduction within the liver, using hematoporphyrin
derivative (Holt et al, 1985), Photofrin (van Hillegersberg et al,
1992), pheophorbide a (Nishiwaki et al, 1989) and aminolaevulinic
acid (Svanberg et al, 1996). Nevertheless, PDT has rarely been
used clinically in treatment of liver tumours, mainly because
of effective accumulation of photosensitizers in liver tissue.
Distribution studies show that photosensitizers are accumulated in
high amounts in reticuloendothelial tissue, such as liver, spleen and
kidney (Bellnier et al, 1989), and in particular, liver tissue contains
high photosensitizer levels after administration (Bown et al, 1986).
Our study showed that BCA concentrations in liver and tumour
tissue were highest 1 h after intravenous administration,
suggesting that in our model system the optimal time interval for
BCA-IPDT treatment would be somewhere within the first 24 h
after BCA administration. This could be of clinical relevance,
because it implies that photosensitizer injection and interstitial
illumination could take place in a single treatment session.
Distribution of BCA resembled the distribution of most other
photosensitizers: high tissue levels in the liver and no tumour
selectivity. The occurring biphasic pharmacokinetics has also
been described by de Smidt et al (1992) for the photosensitizer
bisulphonated tetraphenylporphyrine (TPPS-2A): they attributed
the biphasic kinetics of TPPS-2A to an initial association of the
photosensitizer with the capillary network, followed by redistribu-
tion in the tissue surrounding the vessels. As a consequence,
PDT-induced tumour-killing upon illumination shortly after
photosensitizer administration is likely to be mainly due to 'shut-
down' of tumour vessels and less to a direct killing effect upon
tumour cells. However, tumour selectivity is of minor importance
as long as enough photosensitizer is present at the time of illumi-
nation. Evidently, the selectivity of interstitial treatment relies
mostly on light tissue penetration. Although IPDT with BCA may
induce a rim ofsurrounding liver tissue necrosis, we observed only
a minor increase in serum ALAT and ASAT levels (Table 3).
Induction of a rim of normal tissue damage around a tumour is
even preferable in oncological treatment.
Because hepatic tumours are believed to be mainly supplied by
blood via the hepatic artery (Ackerman et al, 1969), preferential
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uptake in tumour tissue could be established by injecting a photo-
sensitizer directly into the hepatic artery (Nishiwaki et al, 1989;
Purkiss et al, 1994). An additional advantage of this local
administration could be reduction of systemic effects, such as skin
photosensitivity.
Interstitial illumination with BCA as photosensitizer resulted in
extensive tumour necrosis and necrosis of surrounding liver tissue.
Tumours of CC531 cells transplanted to the liver, by subcapsular
inoculation with cultured cells, normally grow with about
60% central necrosis. After PDT, in most cases, tumours were
completely surrounded by a zone ofnecrotic liver tissue. Although
lesion sizes, 2 days after illumination, were larger at illumination
1 h rather than 4 h after BCA administration, the percentage of
tumour necrosis was similar at these time intervals, on average
97%. Twenty-four hours after BCA administration, the amount of
BCA was clearly too low to induce a sufficient phototoxic reac-
tion, which has also been described for bacteriochlorophyll-a, a
precursor of bacteriochlorin a (Henderson et al, 1991).
Induced lesions after illumination 1 h after BCA administration
(141.8 ± 21.9 mm2) were large considering the use of a single bare
fibre with a spot size of 0.6 mm in diameter. Penetration of light
into tissue depends on its optical properties and is mainly deter-
mined by scattering and absorption, which are wavelength depen-
dent (Parsa et al, 1989). Amfield et al (1992) showed that, at a
wavelength of 789 nm, absorption and scattering coefficients were
lower than at a wavelength of 630 nm, resulting in increased pene-
tration of light. Using BCA and light of 760 nm will thus result in
larger lesions compared with Photofrin and illumination with
630 nm, which is an advantage of BCA, especially in highly
pigmented tissue, such as the liver. Larger tissue volumes can be
treated using multiple fibres and modified fibre tips (Amfield et al,
1986). Feasibility ofa multiple-fibre system for use within the liver
has already been demonstrated in humans (Purkiss et al, 1993).
On microscopic examination, islands of viable tumour cells
could be identified in most cases. A relationship between
surviving cells and blood supply ofthe tumour could not be estab-
lished, but is suspected. Korbelik et al (1994) were able to estab-
lish a relationship between the direct killing effect of PDT and the
proximity of tumour cells to the blood supply. In particular, in the
case of bacteriochlorophyll-a, a decrease in concentrations away
from the blood vessels occurred and the greatest killing effect of
PDT was inflicted on cells nearest to blood vessels. Additionally,
as phototoxicity of PDT also depends on the presence of enough
oxygen, a poor vascularization, and thus a reduction in oxygen,
will contribute to less tumour cell killing (Henderson and Fingar,
1989). Therefore, both a reduced photosensitizer concentration
and hypoxic conditions could explain the resistance to BCA-PDT
treatment. The importance ofgetting 100% cell kill in liver metas-
tases is clearly illustrated by our finding that, despite the induction
of 97.8% necrosis, after 35 days tumour sizes did not seem to
differ between treated and untreated animals. Optimizing the treat-
ment protocol could be a possibility to obtain complete tumour
remission in this tumour model. Another way to improve response
rates could be to combine PDT with other treatment modalities,
such as chemotherapy or hyperthermia, which have been shown to
be synergetic with PDT (Waldow et al, 1985; Freitas et al, 1990;
Bremner et al, 1992). Mitomycin c (MMC) given before illumina-
tion has been shown to increase tumour response to PDT with
BCA in a RIF tumour (van Geel et al, 1995).
Microscopic examination of induced lesions within 'normal'
liver tissue showed a sharp border between vital and necrotic liver
tissue. A recurrent phenomenon, however, was the presence of
vital-looking hepatocytes around portal vessels, whereas hepato-
cytes around a central vein did not seem to survive treatment. This
finding is counterintuitive, as blood within the liver flows from
portal vessels to central veins, and thus highest levels of BCA are
to be expected around the portal vessels. A possible explanation
has been suggested by van Hillegersberg et al (1992), who
proposed that survival of hepatocytes is due to a different hepato-
cyte environment (perfusion) and liver cell enzyme content in the
periportal area, preventing induction ofoxidative damage by PDT.
In conclusion, our data suggest that optimal results in IPDT for
liver tumours with the photosensitizer BCA will be obtained by
illumination shortly after BCA administration, and illustrate that
illumination with light of 760 nm is a feasible strategy, potentially
allowing the treatment oflarger tumour volumes.
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